Advertisement

Histiozytosen

  • S. Goerdt
  • L.-U. Wölfer

Zusammenfassung

Die Histiozytosen sind als Neubildungen des mononukleär-phagozytischen Systems anzusehen, dem auch die dendritischen Zellen im weiteren Sinne zuzurechnen sind. Prototypen der dendritischen Zellen sind die epidermalen Langerhans-Zellen deren einzigartigen Charakteristika es erlauben, die Histiozytosen, die sich von diesen Zellen ableiten, als Langerhans-Zellhistiozytosen (LHZ-Histiozytosen) abzugrenzen. Die übrigen Histiozytosen werden als Non-Langerhans-Zellhistiozytosen (N-LHZ-Histiozytosen) zusammengefasst und weisen bezüglich der läsionalen Histiozyten die Merkmale von Makrophagen auf. Die systemischen N-LHZ-Histiozytosen zeigen eine klassische Aktivierung der läsionalen Makrophagen (s. Abschn. 24.3 „Non-Langerhans-Zellhistiozytosen“); die kutanen N-LHZ-Histiozytosen befallen dagegen ganz überwiegend die Haut und leiten sich von alternativ-aktivierten Makrophagen ab (Tabelle 24.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Leenen PJ, Egeler RM (1999) Langerhans’cell histiocytosis is caused by dysregulation of the E-cadherin-beta-catenin cascade: A hypothesis. Immunol Cell Biol 77: 460–467Google Scholar
  2. Lichtenwald D, Jakubovic HR, Rosenthal D (1991) Primary cutaneous Langerhans’cell histiocytosis in an adult. Arch Dermatol; 127: 1545–1548PubMedCrossRefGoogle Scholar
  3. Malone M (1991) Histiocytoses of childhood. Histopathology 19: 105–109PubMedCrossRefGoogle Scholar
  4. Murray S, Rowlinson-Busza G, Morris JF, Chu AC (2000) Diagnostic and therapeutic evaluation of an anti-Langerhans cell histiocytosis monoclonal antibody (NA1/34) in a new xenograft model. J Invest Dermatol 114: 127–134PubMedCrossRefGoogle Scholar
  5. Savell VH Jr, Sherman T, Scheuermann RH, Siddiqui AM, Margraf LR (1998) Bd-2 expression in Langerhans’ cell histiocytosis. Pediatr Dev Pathol 1: 210–215PubMedCrossRefGoogle Scholar
  6. Weintraub M, Bhatia KG, Chandra RS, Magrath IT, Ladisch S (1998) p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol zo: 12–17Google Scholar
  7. Weiss LM (1992) Histiocytic and dendritic cell proliferations. In: Knowles DM (ed) Neoplastic haematopathology. William & Wilkins, Baltimore, p 1459Google Scholar
  8. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG (1994) Langerhans-cell histiocytosis (histiocytosis X)–a clonal proliferative disease. N Engl J Med 21: 154–160CrossRefGoogle Scholar
  9. Wolfer LU, Dippel E, Goerdt S (1999) Histiozytäre Erkrankungen des Kindesalters. In: Traupe H, Hamm H (Hrsg) Pädiatrische Dermatologie. Springer, Berlin Heidlberg New York Tokyo, S 209–234Google Scholar
  10. Yu RC, Chu C, Buluwela L, Chu AC (1994) Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343: 767–768PubMedCrossRefGoogle Scholar
  11. Goerdt S, Orfanos CE (1999) Other functions, other genes: Alternative activation of antigen-presenting cells. Immunity 1o: 137–142Google Scholar
  12. Goerdt S, Bhardwaj R, Sorg C (1993 a) Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol 142: 1409–1422Google Scholar
  13. Goerdt S, Kolde G, Bonsmann G et al. (1993 b) Immunhistochemical comparison of cutaneous histiocytoses and related skin disorders: Diagnostic and histogenetic relevance of MS-1 high molecular weight protein expression. J Pathol 170: 421–427Google Scholar
  14. Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos CE, Schledzewski K, Goerdt S (2001) Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein bIG-H3. Scand J Immunol 53: 386–392PubMedCrossRefGoogle Scholar
  15. Hogger P, Dreier J, Droste A, Buck F, Sorg C (1998) Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor casteine-rich family (CD163). J Immunol 161: 1883–1890PubMedGoogle Scholar
  16. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, Goerdt S (1998) Alternative macrophage activation associated CCchemokine-i, a novel structural homologue of macrophage inflammatory protein- 1a with a The-associated pattern. J Immunol 160: 1411–1418PubMedGoogle Scholar
  17. Ohga S, Matsuzaki A, Nishizaki M, Nagashima T, Kai T, Suda M, Ueda K (1993) Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol 15: 291–298Google Scholar
  18. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 176: 287–292Google Scholar
  19. Teruya-Feldstein J, Setsuda J, Yao X, Kingma DW, Straus S, Tosato G, Jaffe ES (1999) MIP-ialpha expression in tissues from patients with hemophagocytic syndrome. Lab Invest 79: 1583–1590PubMedGoogle Scholar
  20. Gianotti F, Caputo R, Ermacora E (1971) Singular „infantile histiozytosis with cells with intracytoplasmic vermiform particles. Bull Soc Fr Dermatol Syhiligr 78: 232–233Google Scholar
  21. Herbst AM, Laude TA (1999) Juvenile xanthogranuloma: Further evidence of a reactive etiology. Pediatr Dermatol 16: 164 (letter)Google Scholar
  22. Inyengar V, Golomb CA, Schachner L (1998) Neurilemmomatosis NF2, and juvenile xanthogranuloma. J Am Acad Dermatol 39: 83i - 834Google Scholar
  23. Lazova R, Shapiro PE (1999) Junvenile xanthogranuloma versus Langerhans cell histiocytosis (histiocytosis X). Semin Cutan Med Surg 18: 71–77PubMedCrossRefGoogle Scholar
  24. Sangüeza OP, Salmon JK, White CR Jr, Beckstead JH (1995) Juvenile xanthogranuloma: A clinical, histopathologic, and immunohstochemical study. J Cutan Pathol 22: 327–335Google Scholar
  25. Sonoda T, Hashimoto H, Enjoji M (1985) Juvenile xanthogranuloma: Clinicopathologic analysis and immunhistochemical study of 57 patients. Cancer 56: 2280–2286PubMedCrossRefGoogle Scholar
  26. Zvulunov A, Barak Y, Metzker A (1995) Juvenile xanthogranuloma, neurofibromatosis and juvenile chronic myelogenous leucemia: World statistical analysis. Arch Dermatol 131: 904–908Google Scholar
  27. Altmann J Winkelmann RK (1962) Xanthoma disseminatum. Arch Dermatol 86: 682–696Google Scholar
  28. Battaglini J, Olsen TG (1984) Disseminated xanthosiderohistiocytosis, a variant of xanthoma disseminatum, in a patient with a plasma cell dyscrasia. J Am Acad Derrmatol 750–755Google Scholar
  29. Braun-Falco O, Korting HC, Zenicke H, Klövekorn W (1988) Eruptive Histiozytome and Xanthoma disseminatum als Manifestationsformen derselben Erkrankung? Hautarzt 39: 652–657PubMedGoogle Scholar
  30. Ferrando J, Estarch T, Bombi JA, Bassas S, Navarra E, Simon A (1982) Self-healing childhood histiozytosis X (IlligFanconi disease). Comments on ultrastructural aspects and etiopathogenic classification of histiozytosis. Med Cutan Ibero Lat Am 1o: 323–338Google Scholar
  31. Kumakiri M, Sudoh M, Miura Y (1981) Xanthoma disseminatum. Report of a case with histological and ultrastructural studies of skin lesions. J Am Acad Dermatol 4: 291–299Google Scholar
  32. Montgomery H, Osterberg AE (1938) Xanthomatosis. Correlation of clinical histopathologic and chemical studies of cutaneous xanthoma. Arch Dermatol Syphilol 37: 375–402Google Scholar
  33. Powell JJ, Marren P, Wojnarowska F, Davies C (1999) Xanthoma disseminatum with multi-system involvement and fatal outcome. J Eur Acad Dermatol Venereol 12: 276–278PubMedCrossRefGoogle Scholar
  34. Stirling RJ, Bradbury J (1998) Corneal involvement in xanthoma disseminatum. Eye 12: 317–318PubMedCrossRefGoogle Scholar
  35. Tietge UJ, Maschek H, Schneider A, Gawehn AE, Wagner S, Mann MP, Schmidt HH (1998) Xanthoma disseminatum with marked mucocutaneous involvement. Dtsch Med Wochenschr 123: 1337–1342PubMedCrossRefGoogle Scholar
  36. Woollons A, Darley CR (1999) Xanthoma disseminatum: A case with hepatic involvement, diabetes insipidus and type II hyperlipidaemia. Clin Exp Dermatol 23: 277–28oCrossRefGoogle Scholar
  37. Barrow MV, Holubar K (1969) Multicentric retiulohistio- cytosis. A review of 33 patients. Medicine 48: 287–305PubMedCrossRefGoogle Scholar
  38. Candell Chalom E, Elenitsas R, Rosenstein ED, Kramer N (1998) A case of multicentric reticulohistiocytosis in a 6-year-old-child. J Rheumatol 25: 794–797PubMedGoogle Scholar
  39. Goltz RW, Laymon CW (1954) Multicentric reticulohistiocytosis of the skin and synovia. Arch Dermatol 69: 717–730CrossRefGoogle Scholar
  40. Horvath JR, Hoffman GS (1999) Multicentric retriculohistiocytosis: A mimic of gout and rheumatoid arthitis. Cleve Clin J Med 66: 166–172Google Scholar
  41. Orfanos CE, Lämmer D (1980) Retikulohistiozytäre Tumoren der Haut. Neuere Konzepte. Hautarzt 31: 297–307Google Scholar
  42. Rosshoff W, Kratka J, Orfanos CE (1978) Multinoduläre Retikulohistiozytose des Erwachsenen. Hautarzt 29: 578–582PubMedGoogle Scholar
  43. Valencia IC, Colsky A, Berman B (1998) Multicentric reticulohistiocytosis associated with recurrent breast carcinoma. J Am Acad Dermatol 39: 864–866PubMedCrossRefGoogle Scholar
  44. Worm M, Kleine-Tebbe A, von Stebut E, Haas N, Kolde G (1998) Multicentric reticulohistiocytosis indicating metastasis of an unknown primary tumour. Acta Derm Venereol 78: 67–68PubMedCrossRefGoogle Scholar
  45. Zelger B, Cerio R, Soyer HP (1994) Reticulohistiocytoma and multicentric reticulohistiocytosis: Histopathologic and immunophenotypic distinct entities. Am J Dermatopathol 16: 577–584Google Scholar
  46. Caputo R, Ermacora E, Gelmetti C, Berti E, Gianni E, Nigro A (1987) Generalized eruptive histioctoma in children. J Am Acad Dermatol 17: 449–454PubMedCrossRefGoogle Scholar
  47. Goerdt S, Bonsmann G, Sunderkoetter C, Grabbe S, Luger T, Kolde G (1994) A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. J Am Acad Dermatol 31: 322–326PubMedCrossRefGoogle Scholar
  48. Grob JJ, Collet AM, Horchowski N (1988) Histiocytome éruptif généralisé de Winkelmann et Muller. Etude ultra-structurale et immunohistochemique. Ann Dermatol Venerol 115: 1202–1204Google Scholar
  49. Jang KA, Lee HJ, Choi JH, Sung KJ, Koh JK, Moon KC (1999) Generalized eruptive histiocytoma of childhood. Br J Dermatol 14o: 174–176CrossRefGoogle Scholar
  50. Repiso T, Roca-Miralles M, Kanitakis J, Castells-Rodellas A (1995) Generalized eruptive histiocytoma evolving into xanthoma disseminatum in a 4-year-old boy. Br J Dermatol 132: 978–982PubMedCrossRefGoogle Scholar
  51. Stables GI, MacKie RM (1992) Generalized eruptive histiocytoma. Br J Dermatol 126: 196–199PubMedCrossRefGoogle Scholar
  52. Umbert IJ, Winkelmann RK (1989) Eruptive Histiocytoma. J Am Acad Dermatol 20: 958–964PubMedCrossRefGoogle Scholar
  53. Winkelmann K, Muller SA (1963) Generalized eruptive histiocytoma. Arch Dermatol 88: 586–596PubMedCrossRefGoogle Scholar
  54. Finan MC, Winkelmann RK (1986) Necrobiotic xanthogranuloma with paraproteinemia: A review of 22 cases. Medicin (Baltimore) 65: 376–388Google Scholar
  55. Finan MC, Winkelmann RK (1987) Histopathology of necrobiotic xanthogranuloma with paraproteinemia. J Cutan Pathol 14: 92–99PubMedCrossRefGoogle Scholar
  56. Georgiou S, Monastirli A, Kapranos N, Pasmatzi E, Sakkis T, Tsambaos D (1999). Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 79: 484–485PubMedCrossRefGoogle Scholar
  57. Kossard S, Winkelmann RK (198o) Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 3: 257–270Google Scholar
  58. Matsura F, Yamashita S, Hirano K et al. (1999) Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia-a possible pathogenesis of necrobiotic xanthogranuloma. Atherosclerosis 142: 355–365CrossRefGoogle Scholar
  59. McGregor JM, Miller J, Smith NP, Hay RJ (1993) Necrobiotic xanthogranuloma without periorbital lesions. J Am Acad Dermatol 29: 466–469PubMedCrossRefGoogle Scholar
  60. Nestle FO, Hofbauer G, Burg G (1999). Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. Dermatology 198: 434–435PubMedGoogle Scholar
  61. Venencie PY, Puissant A, Verola O (1987) Necrobiotic xathogranuloma with myeloma. Cancer 59: 588–592PubMedCrossRefGoogle Scholar
  62. Burgdorf WH, Kusch SL, Nix TE Jr, Pitha J (1981) Progressive nodular histiocytoma. Arch Dermatol 117: 644–649PubMedCrossRefGoogle Scholar
  63. Taunton OD, Yeshurun D, Jarrat M (1978) Progressive nodular histiocytoma. Arch Dermatol 114: 1505–1508PubMedCrossRefGoogle Scholar
  64. Zelger BWH, Staudacher C, Orchard G (1995) Solitary and generalized variants of spindle cell xanthograuloma (progressive nodular histiocytosis). Histopathology 27: 11–19PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • S. Goerdt
  • L.-U. Wölfer

There are no affiliations available

Personalised recommendations